PubRank

Amin Rahemtulla

Author PubWeight™ 37.63‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood 2012 1.64
2 Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006 1.56
3 Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leuk Lymphoma 2013 1.53
4 Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003 1.49
5 Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003 1.44
6 Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood 2012 1.27
7 Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 2005 1.26
8 Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006 1.21
9 Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 2013 1.20
10 No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. Leuk Res 2005 1.16
11 Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003 1.15
12 Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood 2010 1.08
13 Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma 2005 1.03
14 The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006 1.03
15 Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003 0.99
16 Regulation of multiple myeloma survival and progression by CD1d. Blood 2008 0.98
17 Centromeric repositioning of coreceptor loci predicts their stable silencing and the CD4/CD8 lineage choice. J Exp Med 2004 0.98
18 Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004 0.98
19 Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 2003 0.94
20 Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. PLoS One 2013 0.93
21 Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2011 0.91
22 EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure. Biol Blood Marrow Transplant 2011 0.89
23 Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol 2004 0.89
24 Percutaneous vertebroplasty to treat painful myelomatous vertebral deposits-long-term efficacy outcomes. Ann Hematol 2010 0.86
25 Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Eur J Haematol 2003 0.86
26 New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003 0.85
27 Lack of correlation between emergence of an abnormal protein band or of oligoclonal bands and survival in patients with multiple myeloma achieving complete remission following autologous stem cell transplantation. Haematologica 2011 0.84
28 Current treatment options for myeloma. Expert Opin Pharmacother 2005 0.84
29 Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation. Biol Blood Marrow Transplant 2010 0.84
30 Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood 2010 0.83
31 Anti-angiogenic effect of bortezomib in patients with multiple myeloma. Acta Haematol 2005 0.82
32 Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease. J Clin Invest 2015 0.81
33 Bisphosphonate treatment for multiple myeloma. Drugs Today (Barc) 2004 0.79
34 The role of markers of bone remodeling in multiple myeloma. Blood Rev 2005 0.78
35 Excess bone marrow B-cells in patients with multiple myeloma achieving complete remission following autologous stem cell transplantation is a biomarker for improved survival. Br J Haematol 2011 0.78
36 Human invariant NKT cells are required for effective in vitro alloresponses. J Immunol 2005 0.78
37 Azurophilic granules in myeloma cells. Am J Hematol 2014 0.77
38 Rapid initial response of myeloma hyperammonemic encephalopathy to L-ornithine-L-aspartate and dexamethasone therapy. Leuk Lymphoma 2013 0.75
39 Interactive web-based guidelines for chronic myeloid leukaemia. Lancet 2004 0.75
40 Bone marrow aspirate and trephine biopsy findings in lymphoplasmacytic lymphoma. Am J Hematol 2011 0.75
41 Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. Br J Haematol 2011 0.75
42 LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematol Oncol 2010 0.75
43 Images in cardiovascular medicine. Intermittent loss of second heart sound. Circulation 2006 0.75
44 Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors. Cancer Cell 2014 0.75